Kim Theilgaard-Mønch
Clinical Associate Professor, Group leader
Department of Clinical Medicine
Blegdamsvej 9, 2100 København Ø
Theilgaard Group
Ole Maaløes Vej 5
2200 København N.
Member of:
ORCID: 0000-0002-4239-4939
1 - 2 out of 2Page size: 10
- 2015
- Published
Cellular origin of prognostic chromosomal aberrations in AML patients
Mora-Jensen, H., Jendholm, L. J., Rapin, N. P. J., Andersen, M. K., Roug, A. S., Bagger, F. O., Bullinger, L., Winther, Ole, Borregaard, N., Porse, Bo Torben & Theilgaard-Mønch, Kim, 11 Feb 2015, In: Leukemia. 29, p. 1785-1789 5 p.Research output: Contribution to journal › Journal article › Research › peer-review
- Published
ERG promotes the maintenance of hematopoietic stem cells by restricting their differentiation
Knudsen, K. J., Rehn, M. C., Hasemann, M. S., Rapin, N. P. J., Bagger, F. O., Ohlsson, E. K., Willer, A., Frank, Anne-Katrine, Søndergaard, E., Jendholm, L. J., Thorén, L. A. M., Lee, J., Rak, J., Theilgaard-Mønch, Kim & Porse, Bo Torben, 2015, In: Genes & Development. 29, p. 1915-1929 15 p.Research output: Contribution to journal › Journal article › Research › peer-review
ID: 3997971
Most downloads
-
2493
downloads
HemaExplorer: a database of mRNA expression profiles in normal and malignant haematopoiesis
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
80
downloads
Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
37
downloads
Phosphorylation of SHP2 at Tyr62 enables acquired resistance to SHP2 allosteric inhibitors in FLT3-ITD-driven AML
Research output: Contribution to journal › Journal article › Research › peer-review
Published